Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. (From -To) Objective: O varian can cer is the leadi ng cau se of death from g ynecologic maligna ncies i n the Weste rn worl d. Fibrobla st growth factor receptor (FGFR) signaling has been implicated to play a role in ovarian tumorigenesis. Given our recent report of activating mutations in FGFR2 in endometrioid endometrial tumors and the similarities in the molecular genetics of ovarian and endometrial cancer, we hypothesized that a ctivating FG FR2 mutations m ay also o ccur in a subset of ovaria n tumors, particularly in the e ndometrioid subtype. Methods: Six exons of F GFR2 were sequenced in 120 ovarian tumors representing the various histotypes of o varian cancer. Results: Mutation of FGFR2 was detected at lo w frequency in endometrioid (1/46, 2.2%) and serous (1/41, 2.4%) ovarian cancer. No mutations were detected in clear cell, mucinous, or mixed histology tumors or in the ovarian cancer cell line s te sted. Fun ctional ch aracterization of the FGFR2 mutations confirmed that the mutations detected in ovarian cancer result in receptor activation. Conclusions: Despite the low incidence of FGFR2 mutations in ovarian cancer, the development and validation of anti-FGFR agents in other cancer types may allow for the future use of these agents in the small subset of ovarian cancer patients whose tumors possess activating FGFR2 mutations.
Introduction.
The molecular pathology of ovarian carcinomas is heterogenous with multiple precursor lesions and multiple pathways of tumor development. The four most common histological subtypes are serous, endometrioid, mucinous and clear cell carcinoma and the different etiologies of these various histotypes is supported by the presence of different underlying molecular genetic alterations eg PTEN mutations are common in endometrioid but not serous or mucinous ovarian carcinomas. Similar histological subtypes are observed in carcinoma of the endometrium and there is a high degree of similarity regarding the molecular genetics of endometrial carcinoma and ovarian carcinoma with mutations in TP53, PTEN, KRAS, PIK3CA and b-catenin identified in both tumor types, albeit sometimes at different frequencies in the different histological subtypes of both cancers. The endometrioid subtype of ovarian carcinoma bears close histological resemblance to endometrioid carcinoma of the endometrium, indeed clear cell and endometrioid carcinomas of the ovary are often histologically associated with endometriosis. Similar molecular genetic alterations have been reported in adjacent endometriosis and synchronous endometrioid carcinomas of the ovary, supporting endometriosis as a possible precursor for both endometrioid and clear cell carcinomas of the ovary. Moreover, population based cohort studies have indicated a higher incidence of ovarian cancer in women with endometriosis (1) . We identified mutations in FGFR2 in endometrioid endometrial cancer (2) and demonstrated oncogene dependence as inhibition of FGFR2 resulted in growth arrest and cell death (3) . As FGF signaling had been implicated in the pathogenesis of ovarian cancer (4) we hypothesized that FGFR2 might be activated in a subset of ovarian cancers, most likely those demonstrating an endometrioid or clear cell histology.
Body. Specific Aim 1A. Determine the mutation frequency of FGFR2 in a panel of ovarian cancer cell lines and ovarian carcinomas representing the different histological subtypes of ovarian cancer
The four most common histolo gical subtypes of ova rian cancer are serou s (80-85%) , endometrioid (10%), clear cell (5 %), and mucinous (3%) [2] . 120 fre sh frozen o varian tumo r samples from multiple institutions were used in this study, including 46 endometrioid, 41 serous, 14 mucinous, 12 clear cell, and 7 mixed histology ovarian tumors. Ovarian tumor samples were obtained fro m Ian Campbell at the Peter MacCallum Can cer Institu te (26 endometrioid, 32 serous, 10 mucinous, 5 clear cell, and 3 mixed histology ovarian tumors), Michael Birrer at the National Cancer Institu te (5 endometrioid, 9 serous, 4 mucinous, an d 7 clear cell, 4 mixed histology), and Paul Go odfellow at Washington University (15 endomet rioid tumors). The latter 15 tumors from Dr Goodfellow were sequence d prior to the initiation o f this DoD funded study. The majority of specimens used in th is study containe d >80% tu mor epithelial cells, as determined by H&E staining of multi ple sections. In some tumors where this was no t the case, samples were microdissected from serial fresh fr ozen sections to provide specimens with >80% neoplastic cellularity. Ovarian tu mor DNA pr ovided by Dr Ian Campbell underwent whole genome amplificat ion ( WGA) using the Repli-G Phi-medi ated amplification syste m (Qiagen, Hilden, Germany). To minimize the potential for generation of artifacts, WGA was carried out in triplicate, using 25 ng o f primary DNA, and the products were pooled. DNA fro m six ovaria n cancer cell lines (CAOV3, SKOV3, ES-2, OV CAR-3, SWS-26, TOV-21G) was also screened. Additional attempts were made to obtain additional ovarian tumors with a clear cell histology but these were unsuccessful.
120 ovarian tumor samples were screened for FGFR2 mutations in exons 7, 8, 9, 10, 13, and 15, as previously described [20] . We have optimized IHC of FGFR1-FGFR4. All four FGFRs are expressed in many ovarian tumors. We initially proposed to look at a subset of the relevant FGF ligands and correlate the expression of the FGF ligands with the cognate receptor. We originally looked at FGF1, FGF2 and FGF7 however the staining pattern seen with FFG1 and FGF7 was identical suggesting that these antibodies demonstrated crossreactivity. Further investigation revealed that many of the FGF antibodies available, while capable of neutralizing the activity of the ligand to which they had been raised, had not been assessed for specificity. We therefore purchases 18 myc-tagged expression constructs (Origene) for ech of the FGF ligands. These were then sequence verified and transduced into BaF3 cells (that express no endogenous FGFs or FGFRs) and polyclonal stable cell lines were selected with 1200ug/mL G418. We have now generated total cell lysates from all of these cell lines and studies to confirm antibody specificity have been initiated. We have currently evaluated antibodies against FGF1 (n=2), FGF2 (1), FGF3 (2), FGF4 (1), FGF7 (2), FGF9 (1) and FGF10 (2) . As shown in Figure 1A , suitable antibodies against FGF1, 2, 3 & 4 have now been identified. No cross reactivity is observed in cell lines transduced with related FGF ligands, evidenced by the expression of the myc-tagged ligands. As part of the optimization process, new antibodies are run against lysates from stably transfected BaF3 lines expressing the individual FGF ligands. Antibodies are acceptable for subsequent IHC only if they meet all the following criteria: 1) they detect the correct molecular size band; 2) they do not cross react with other proteins and 3) they do not cross react with other members of the FGF family. Figure 1B shows examples of antibodies that failed the screening process for a number of different reasons. The antibody against FGF3 does not detect FGF3 but cross reacts with a number of non-specific high molecular weight proteins; the 2 antibodies against FGF7 do not detect any protein by Western blotting; and the antibody against FGF10 does detect FGF10 but also cross reacts with other proteins making it unsuitable for IHC.
Specific Aim 2a. Test the hypothesis that FGFR2 activation drives transformation of primary ovary surface epithelial (OSE) cells by transducing immortalized OSE cells with wildtype and constitutively activated FGFR2 and assaying for changes in proliferation and anchorage independent growth.
As the rate of FGFR2 mutations was very low in ovarian cancer, we chose to determine whether the mutations we detected resulted in receptor activation using the BaF3 proliferation assay rather than focus on OSE cells. These cells do not express endogenous FGF ligands or FGFRs and introduction and activation of FGFRs has been shown to substitute for IL-3 to promote cell proliferation [29] . Mitogenic assays in the IL-3-dependent BaF3 cells could therefore be used to determine if the Y376C mutation in FGFR2 resulted in ligand independent or dependent receptor activation. The S252W and Y376C mutations were first introduced to the pEF1a.FGFR2b.IRES.neo plasmid (NM_022970.3) using the Quikchange XL Site Directed Mutagenesis Kit (Stratagene) according to manufacturer's instructions. After restriction enzyme screening, the entire coding sequence of FGFR2 was sequenced for each clone to confirm the presence of the intended mutation and to ensure that no other mutations were introduced during the mutagenesis process. BaF3 cells were transduced with empty vector, wildtype FGFR2b and mutant FGFR2b using Amaxa nucleofection and stably selected in 1.2 mg/mL Geneticin in the presence of 5 ng/ml IL-3 for 14 days. For the proliferation assays, cells were washed in PBS to remove IL-3, and plated at 1 x 10 4 cells per well in triplicate in a 96 well plate in IL-3 free media containing 1nM FGF7 and 5 mg/mL heparin. Cells had a 50% volume media change on day 3 to provide fresh FGF ligand. On day five, bioluminescent measurement of ATP was assessed as an indicator of cell number using the ViaLight Plus Cell Proliferation/Cytotoxity Kit (Lonza Rockland, Inc.). Experiments were performed twice in each of two independent sets of stable cell lines, with triplicate wells measured for each assay. As shown in Figure 3 A, the Y37 6C mutation result s in ligand ind ependent re ceptor activation, a s evidenced by BaF3 proliferation in the absence of FGF ligand. Stimulation with FGF7 resulted in increased proliferation in the Y376C FGFR2b BaF3 cells compared to wildtype FGFR2b ( Figure 3B ), d emonstrating that this mutant receptor can be further act ivated by the addition of ligand. In comparison, the S252W mutation does not lead to BaF3 proliferation in the absence of ligand, similar to wildtype FGFR2b ( Figure 3A ) but does lead to in creased BaF3 proliferation in response to its cog nate ligand ( Figure 3B ), consisten t with publish ed literature Based on the low frequency of FGFR2 mutations identified in ovarian tumors and the lack of an ovarian cancer cell line carrying an activating mutation in FGFR2, we did not complete this aim. Although we only sequenced six cell lines, we performed extensive searches on the COSMIC (Catalog of somatic mutations in Cancer) website (http://www.sanger.ac.uk/genetics/CGP/cosmic/) and did not identify an ovarian cell line with an FGFR2 mutation. We did however determine that the mutations we identified resulted in receptor activation (see Aim 2A). We allocated the resources from this aim to Aim 1b as the optimization of antibodies to detect FGF receptors and ligands was much more difficult than expected. 
Key Research Accomplishments
• We screened 120 ovarian tumor for mutations in FGFR2
• Mutation of FGFR2 was detected at low frequency in endometrioid (S252W, 1/46, 2.2%) and serous (Y376C, 1/41, 2.4%) ovarian cancer. No mutations were detected in clear cell, mucinous, or mixed histology tumors or in the ovarian cancer cell lines tested.
• IHC revealed expression of all four FGFRs in ovarian carcinomas. Each carcinoma frequently expressed more than one FGFR.
• We determined that the sensitivity and specificity of many of the existing antibodies detecting many of the FGF ligands was poor.
• We have made stable BaF3 cell lines expressing each of the 18 FGF ligands to enable proper evaluation of the specificity of FGF antibodies The late stage of diagnosis, resistance to chemotherapy, and heterogeneous nature of 65 ovarian can cer m ake it a clin ically challenging diseas e, with an overall 5-year surv ival rate of 66 only 46% [1] . The four m ost co mmon histological subtypes of ovarian cancer are serous (8085%), endometrioid (10%), clear cell (5%), and m ucinous (3%) [2] . The different etiologies of 68 these various histotypes are supported by the presence of different underlying genetic alterations. 69
For example, TP53 mutations are most prevalent in ser ous and high-grade endom etrioid ovarian 70 carcinomas [3] , whereas PTEN, PIK3CA, and CTNNB-1 (β-catenin) mutations are more common 71 in low-grade endom etrioid ovarian cancer [4] [5] [6] (Fig ure 1B) , consisten t with publishe d literatu re [22] . We should note that th ese 246 functional studies were carried ou t using the "b" isoform of FGFR 2 as the effect of the Y376C 247 mutation on receptor dimerization is independent of the "b" or "c" isoform on which it arises.
In conclusion, we identified an S252W mutation, the most predom inant m utation 249 identified in endometrioid endometrial cancers, in a single endometroid ovarian carcinoma and a 250 Y376C m utation in a single serous ovarian tumor. This S252W mutation violates the ligand 251 binding specificity of FGFR2b and FGFR2c and phenotypically m imics the occurrence of 252 FGFR2 isoform switching previously observed in ova rian ca ncer. Together th is da ta rais es th e 253 possibility that inhib ition of FG FR2 by either s mall molecule kinase in hibitors or e xtracellular 254 blocking antibodies may be beneficial in those rare tumors with activating mutations, in addition 255 to the larger number of tumors that undergo FGFR2 isoform switching. 256
